kanilad 100 mg apvalkotās tabletes
medochemie ltd., cyprus - lakozamīds - apvalkotā tablete - 100 mg
brilleve 75 mikrogrami/20 mikrogrami tabletes
sandoz d.d., slovenia - gestodenum, ethinylestradiolum - tablete - 75 µg/20 µg
kanilad 50 mg apvalkotās tabletes
medochemie ltd., cyprus - lakozamīds - apvalkotā tablete - 50 mg
kanilad 200 mg apvalkotās tabletes
medochemie ltd., cyprus - lakozamīds - apvalkotā tablete - 200 mg
brilleve 75 mikrogrami/30 mikrogrami tabletes
sandoz d.d., slovenia - gestodenum, ethinylestradiolum - tablete - 75 µg/30 µg
iamna 60/15 mikrogramu apvalkotās tabletes
sandoz d.d., slovenia - gestodenum, ethinylestradiolum - apvalkotā tablete - 60 µg/15µg
kanilad 150 mg apvalkotās tabletes
medochemie ltd., cyprus - lakozamīds - apvalkotā tablete - 150 mg
lacosamide ucb
ucb pharma s.a. - lacosamide - epilepsijas, daļēji - antiepileptics, - lacosamide ucb ir norādīts kā monotherapy un adjunctive terapiju daļēju sākums lēkmju ar vai bez sekundāras vispārināšanas pieaugušajiem, pusaudžiem un bērniem no 4 gadu vecuma ar epilepsiju.
lacosamide fresenius kabi 10 mg/ml šķīdums infūzijām
fresenius kabi polska sp.z o.o., poland - lakozamīds - Šķīdums infūzijām - 10 mg/ml
lacosamide adroiq
extrovis eu ltd. - lacosamide - epilepsija - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.